ORILISSA® (ELAGOLIX): AN APPROVED TREATMENT FOR ENDOMETRIOSIS
ORILISSA® is an orally-administered, non-peptide small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland.
GnRH is a peptide that simulates the secretion of the pituitary hormones that are responsible for sex steroid production and normal reproductive function.
On July 24, 2018, AbbVie, in collaboration with Neurocrine Biosciences, announced FDA approval for ORILISSA for the management of endometriosis with associated moderate to severe pain. AbbVie began commercialization of ORILISSA in the United States in August 2018.